- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03100110
NeuroCognitive Communicator: Safety Study (NCC-1701)
July 28, 2022 updated by: Ottawa Hospital Research Institute
NeuroCognitive Communicator Exploratory Safety Study of an Assistive Neuroprosthetic Device for Patients With Severe Upper Motor Disability.
Individuals suffering from tetraplegia as a result of cervical spinal cord injury, brainstem stroke, or amyotrophic lateral sclerosis (ALS) cannot independently perform tasks of daily living.
In many cases, these conditions do not have effective therapies and the only intervention is the provision of assistive devices to increase independence and quality of life.
However, currently available devices suffer from usability issues and are limiting for both the patient and caregiver.
One of the most progressive alternative strategies for assistive devices is the use of brain-computer interface (BCI) technology to translate intention signals directly from sensors in the brain into computer or device action.
Preclinical primate research and recent human clinical pilot studies have demonstrated success in restoring function to disabled individuals using sensors implanted directly in motor regions of the brain.
Other preclinical primate research has demonstrated effective intention translation from sensors implemented in cognitive regions of the brain and that this information complements information from the motor regions.
The current proposal seeks to build on these studies and to test the safety aspects related to implanting two sensors, each a microelectrode array, into both the motor and cognitive regions of the brain in motor impaired humans.
Secondary objectives include feasibility evaluation of the complementary sensors in their ability to support effective assistive communication.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
2
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert Doole, MSc
- Phone Number: 647-563-3141
- Email: rdoole@ohri.ca
Study Contact Backup
- Name: Adam J Sachs, MD
- Phone Number: 14471 613-798-5555
- Email: asachs@toh.ca
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Recruiting
- The Ottawa Hospital
-
Contact:
- Robert Doole, MSc
- Phone Number: 6475633141
- Email: rdoole@ohri.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented diagnosis of a complete or incomplete cervical spinal cord injury, with stable neurological deficits greater than 1 year, or ALS with equivalent degree of deficit.
- Maintain some level of communication, enough to independently provide informed consent for the study.
- Deemed healthy for surgery.
- Good psychological and social stability.
- Prospective participants with ALS must already have an advanced directive with regard to ventilation.
- Live within a one-hour travel duration of the site.
Exclusion Criteria:
- Presence of previous certain implanted devices.
- In the opinion of the investigator, the presence of other serious disease or disorder that could affect ability to participate in this study.
- Ongoing participation in another clinical trial.
- Individuals who are immunosuppressed or who have conditions that typically result in immunocompromise (eg. chronic corticosteroid use, immunomodulators, chemotherapy).
- Presence of clinical depression that is not medically optimized, as screened by a neuropsychologist on our team.
- Presence of cognitive deficits, as assessed by a neuropsychologist on our team, that would preclude completion of some cognitively challenging tasks.
- The participant has plans to move outside the study radius within the study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DEVICE_FEASIBILITY
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NeuroCognitive Communicator
|
Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse events
Time Frame: 6 months
|
Transcutaneous connector will be assessed by physician 3-4 times per week for skull and scalp health and lack of infection. All adverse events associated with the system will be measured. |
6 months
|
Change in quality of life as assessed by McGill Quality of Life questionnaire.
Time Frame: 6 months
|
McGill Quality of Life questionnaire will be administered monthly; shortened version will be administered 3-4 times per week.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of allotted time spent with each augmentative and assistive communication technology.
Time Frame: 6 months
|
At the end of most experimental sessions, the participant will have time to operate the NCC to control augmentative and assistive communication (AAC) technologies such as robotic arms or spellers.
We will measure the percentage of allotted time that the participant spends operating each AAC technology, or choosing not to operate any AAC technology.
The data will be aggregated across all AAC sessions with time allotted to AAC operation.
|
6 months
|
Information transfer rate (measured in bits per second) achieved by each participant calculated during closed-loop operation of the neuroprosthetic device, aggregated across trials within a task.
Time Frame: 6 months
|
Participants will perform repeated trials of experimental tasks designed to activate recorded brain regions.
Task progression will be modulated by neuronal activity.
Successful completion of the task will require volitional modulation of neuronal activity.
Task performance will be quantified by the information transfer rate which is calculated from the number of bits of information communicated by each trial's selection(s) and the amount of time it took to complete a trial.
|
6 months
|
Coefficients of neuronal activity covariance matrix and their dependence on task performance.
Time Frame: 6 months
|
Neuronal activity time series covary across neurons within a brain region and across brain regions.
The degree of covariance will be recorded in the coefficients of the covariance matrix, scaled from -1 to +1.
The covariance matrix will be recorded under different task conditions.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 13, 2019
Primary Completion (ANTICIPATED)
April 15, 2024
Study Completion (ANTICIPATED)
April 15, 2024
Study Registration Dates
First Submitted
February 21, 2017
First Submitted That Met QC Criteria
March 28, 2017
First Posted (ACTUAL)
April 4, 2017
Study Record Updates
Last Update Posted (ACTUAL)
August 1, 2022
Last Update Submitted That Met QC Criteria
July 28, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20170100-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tetraplegia
-
Hospices Civils de LyonCompletedTetraplegia C5-C6 | Tetraplegia C6-C7France
-
Virginia Commonwealth UniversityMedical University of South Carolina; Eunice Kennedy Shriver National Institute...CompletedQuadriplegia/TetraplegiaUnited States
-
University of OsloOslo University Hospital; Sunnaas HospitalCompletedSpinal Cord Injured, TetraplegiaNorway
-
Virginia Commonwealth UniversityNational Institute on Disability, Independent Living, and Rehabilitation... and other collaboratorsRecruitingTetraplegia/TetraparesisUnited States
-
University Hospital, GrenobleRecruitingTraumatic Tetraplegia With Cervical Cord InjuryFrance
-
Hospices Civils de LyonRecruitingIndividuals With C6-C7 Tetraplegia (AIS A or B)France
-
VA Palo Alto Health Care SystemONWARD Medical, Inc.Not yet recruitingTetraplegiaUnited States
-
Sheba Medical CenterWithdrawnWheelchair Rugby Players With TetraplegiaIsrael
-
VA Palo Alto Health Care SystemCompletedParaplegia and TetraplegiaUnited States
-
Swiss Paraplegic Centre NottwilCompleted
Clinical Trials on NeuroCognitive Communicator
-
Emory UniversityCompletedCommunication | Positive-Pressure RespirationUnited States
-
University Health Network, TorontoRecruiting
-
Centre Hospitalier Universitaire de NiceCompleted
-
National University Hospital, SingaporeRecruitingPostoperative Delirium | Hip FracturesSingapore, Japan, Korea, Republic of, Malaysia, Thailand
-
Ziekenhuis Oost-LimburgCompleted
-
Corporacion Parc TauliFundació La Marató de TV3Completed
-
Stanford UniversityWithdrawnSleep Apnea, Obstructive | ObesityUnited States
-
St. Jude Children's Research HospitalSt. Baldrick's FoundationCompletedStem Cell Transplant During Childhood | Allogeneic Bone Marrow Transplant During ChildhoodUnited States
-
University of Alabama at BirminghamNot yet recruitingHIV | Aging | Older Adults | Cognitive Training | Cognitive Function AbnormalUnited States
-
Société des Produits Nestlé (SPN)Completed